| 1 |
Reduced tumorgenicity [49]. |
Oncogenicity of transcription factors [49]. |
| 2 |
Great source for disease modeling [95]. |
Inadequate knowledge about optimal time window and cell dose [96]. |
| 3 |
Ability to differentiate into neural cells, NPCs, and vascular endothelial cells in vitro [97, 98]. |
No clinical trial evidence. |
| 4 |
It can be derived from various kinds of cells [97, 98]. |
Needs more specific vehicles for transplantation, which is broadly researched [42, 99]. |
| 5 |
Easier methods are available for cell isolation than using bone marrow or embryonic stem cells [100]. |
Cells take a longer route to become neurons. Therefore, experimental errors become more likely to happen. |
| 6 |
Reduced possibility of immune rejection after autologous transplantation [101]. |
Stimulating the inflammatory response because of viral vehicles or vectors [102]. |
| 7 |
Less ethical problems because of autologous implantation [101]. |
Reprogramming may lead to epigenetic or genetic alterations [103]. |
